CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
September 2020—NeuMoDx Molecular has received the CE mark for its NeuMoDx HPV Assay, a fully automated, in vitro real-time PCR-based assay for the qualitative detection of high-risk types of human papillomavirus DNA in cervical specimens. It specifically identifies HPV 16 and 18 while concurrently detecting 13 other common high-risk types at clinically relevant infection levels.
The test was developed in collaboration with Self-screen BV (Amsterdam) and runs on the NeuMoDx 96 and NeuMoDx 288 molecular systems.
Pages: 1 2